Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced plans to build a dedicated distributor network to support commercialization of its peptide portfolio across ...
Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced an exclusive licensing and manufacturing agreement with LyoGenesis Plus ("LyoGenesis"), a cGMP ...
Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist
Caresyntax will design and operate a multi-phase real-world evidence program for Vector, culminating in a prospective comparative registry across a network of partner surgical facilities. The program ...
Vector Science and Therapeutics Corp. (TSXV: PAIN), a pharmaceutical-grade peptide and precision drug delivery company, today ...
14-Year MLB Veteran and 2016 World Series Champion Joins Valor, Vector's Athlete Platform, to Make Sure the Next Generation Plays Longer and Hurts Less MEQUON, Wis., June 12, 2026 /PRNewswire/ -- ...
Former Wisconsin Governor and U.S. Secretary of Health and Human Services Brings Extensive Healthcare Leadership to Pioneer of Transdermal Drug Delivery Technology MEQUON, Wis., April 30, 2026 /CNW/ - ...
LODI, Wis., Oct. 2, 2025 /CNW/ -- Vector Science & Therapeutics today announced the appointment of Tabitha Hendren as Director, Engineering and Design. Hendren will report to Chief Technology Officer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results